Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00176_DB01151_nanopub.RA7um-WeDWhCBDrY8n2KqQPg1nQibzRsqk14DiXFC3Ow0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00176_DB01151 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00176_DB01151 label "DDI between Fluvoxamine and Desipramine - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed. [drugbank_resource:DB00176_DB01151]" assertion.
- drugbank_resource:DB00176_DB01151 identifier "drugbank_resource:DB00176_DB01151" assertion.
- drugbank_resource:DB00176_DB01151 title "DDI between Fluvoxamine and Desipramine - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00176 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB01151 assertion.
- drugbank:DB01151 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB01151 assertion.